5-tert-butyl-4,5,6,7-tetrahydroindazole | 136812-35-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-tert-butyl-4,5,6,7-tetrahydroindazole
• 英文别名: 5-tert-butyl-4,5,6,7-tetrahydro-1H-indazole
• CAS: 136812-35-6
• 化学式: C₁₁H₁₈N₂
• 分子量: 178.277
• InChiKey: ZACRSKVQGWDJKR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  N<2-(dimethylamino)methylene>-4-tert-butylcyclohexan-1-one 在 一水合肼 作用下， 以 乙醇 为溶剂， 反应 18.0h， 以100%的产率得到5-tert-butyl-4,5,6,7-tetrahydroindazole
  参考文献：
  名称：

  Tetramethylammonium Glycinate: A New Reagent for Improved Pyrrole Synthesis by [3+2] Cyclization

  摘要：

  The novel reagent tetramethylammonium glycinate has been introduced as the most effective glycine derivative for the convenient synthesis of 4,5,6,7-tetrahydroisoindoles (or pyrroles unsubstituted in the 2 and 5 positions) from 1,3-dicarbonyl compounds by [3+2] cyclization. The reaction has been shown to be catalyzed by 2,6-di(tert.butyl)pyridine reagents to triple the reported yield.

  DOI：

  10.1080/00397919108021790

文献信息

• CYCLOHEXYLPYRAZOLE-LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1
  申请人：Aicher Thomas Daniel

  公开号：US20090111800A1

  公开（公告）日：2009-04-30

  The present invention discloses novel compounds of Formula (I): having 11β-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I), as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11β-HSD type 1 activity.

  本发明公开了具有11β-HSD类型1拮抗活性的Formula (I)的新化合物，以及制备这种化合物的方法。在另一实施例中，该发明公开了包含Formula (I)化合物的药物组合物，以及利用这些化合物和组合物治疗糖尿病、高血糖、肥胖、高血压、高脂血症、代谢综合征以及与11β-HSD类型1活性相关的其他疾病的方法。
• NEW DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE
  申请人：Hoffmann-La Roche Inc.

  公开号：US20150099734A1

  公开（公告）日：2015-04-09

  The invention provides novel compounds having the general formula (I) wherein R 1 , R 2 , Y and W are as described herein, compositions including the compounds and methods of using the compounds.

  这项发明提供了具有一般化学式（I）的新化合物，其中R1、R2、Y和W如本文所述，包括该化合物的组合物以及使用该化合物的方法。
• DIPEPTIDE AND TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS
  申请人：ONYX THERAPEUTICS, INC.

  公开号：US20160031934A1

  公开（公告）日：2016-02-04

  Provided herein are dipeptide and tripeptide epoxy ketone protease inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula (X): and pharmaceutically acceptable salts and compositions including the same. The compounds and compositions provided herein may be used, for example, in the treatment of proliferative diseases including cancer and autoimmune diseases.

  本文提供了二肽和三肽环氧酮蛋白酶抑制剂，其制备方法，相关的药物组合物以及使用方法。例如，本文提供了化合物X的公式和包括其在内的药学上可接受的盐和组合物。本文提供的化合物和组合物可以用于治疗增殖性疾病，包括癌症和自身免疫性疾病。
• NEW BICYCLIC DERIVATIVES
  申请人：Hoffmann-La Roche Inc.

  公开号：US20150353559A1

  公开（公告）日：2015-12-10

  The invention provides novel compounds having the general formula (I) wherein R 1 , Y, A, W, R 2 , m, n, p and q are as described herein, compositions including the compounds and methods of using the compounds.

  本发明提供了具有一般式(I)的新化合物，其中R1、Y、A、W、R2、m、n、p和q如此处所述，包括该化合物的组合物以及使用该化合物的方法。
• Bicyclic compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors
  申请人：Hoffmann-La Roche Inc.

  公开号：US10654857B2

  公开（公告）日：2020-05-19

  Compounds of formula (I) wherein R1, R2, A, W, m, n, p and q are as described herein, compositions including the compounds and methods of using the compounds as autotaxin inhibitors.

  式(I)化合物 其中 R1、R2、A、W、m、n、p 和 q 如本文所述。